ALFA Finder| Revenue growth | Q4 revenue grew 50.2% YoY; FY26 revenue up 18.9% organic. |
|---|---|
| Margins | FY26 EBITDA margin slightly lower at 35.5% vs 37.4% YoY. |
| Demand visibility | Strong traction in regulated markets; Europe remains the largest market (40%). |
| Management confidence | Confident, highlighting steady demand across key therapeutic segments and global markets. |
Growth
FY26 revenue grew 18.9% YoY to ₹827.87cr; Q4 revenue jumped 50.2% to ₹276.53cr. EBITDA grew 12.8% in FY26.
Outlook
Capacity utilization rose to 74% from 70%. Expanding via land acquisitions at Isambe and Patalganga.
Risks
EBITDA margins contracted from 37.4% to 35.5% YoY; PAT margin also dipped slightly to 25.3%.
Earnings Call filed with NSE, NSE: SUPRIYA. Summary written with AI assistance from the document.
Supriya Lifescience Ltd: key numbers
- Share price
- ₹632.10
- Market cap
- ₹5,087 Cr
- Revenue (annual)
- ₹827.9 Cr
- Net profit (annual)
- ₹209.1 Cr
- P/E (TTM)
- 28.7×Sector 43.7×
- Promoter holding
- 68.30%+0.00% QoQ
- FII holding
- 6.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Supriya Lifescience Ltd
All →Supriya Lifescience Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹206 Cr (+3.2% YoY), EBITDA ₹45 Cr (-37.5%), margin 22%. LATAM regulatory shock, Ambernath ramp-up costs and raw material inflation hit margins; FY27 margin guidance cut to 23–25%.
- Call
- Guides 20% growth
Supriya Lifescience Results Update
Supriya Lifescience's Q2 FY27 revenue rose 3.2%, but EBITDA and PAT fell sharply. Ambernath ramp-up costs and LATAM regulatory shifts hurt margins.
Supriya Lifescience Q2 FY27 Results: Net Profit ₹29.2 Cr, Down 42.1% YoY
Supriya Lifescience Ltd reported revenue from operations of ₹206.3 Cr (+3.3% YoY) and net profit of ₹29.2 Cr (-42.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29.2 Cr · -42.1% YoY
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Supriya Lifescience Board Meeting Date
Supriya Lifescience will hold a board meeting on 6 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after results are declared.
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed a pending case was admitted by the Supreme Court. An interim order precludes coercive action against directors while the matter is sub judice.